QNCX vs XYL · $79.3M cap vs P/E 27, rev $4.46B
Quince Therapeutics, Inc. (QNCX) versus Xylem Inc (XYL) — a side-by-side from cached financials, not a winner call.
Quince Therapeutics, Inc. (QNCX) is a biotechnology company listed on US.
Xylem Inc (XYL) is a specialty industrial machinery company listed on NYSE.
QNCX does not have a complete income-statement cache yet.
Latest reported XYL revenue for 2026-06-30 was $4.46B. Net income was $456.0M. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
QNCX currently screens at market cap $79.3M. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
Not investment advice. Open the QNCX and XYL stock pages for the full models.
Not investment advice.